Doxycycline Postexposure Prophylaxis for STIs in Women — Uncertain Benefit, Urgent Need

The global incidence of reportable sexually transmitted infections (STIs), including gonorrhea, chlamydia, and syphilis, remains high and in some populations has relentlessly increased. In the United States in 2021, the incidence of early syphilis among men who have sex with men surpassed any previous record.1 The human and economic consequences of untreated STIs can be severe. Moreover, concurrent acquisition of human immunodeficiency virus (HIV) infection and another STI continues to occur, especially with a lack of HIV preexposure prophylaxis (PrEP), and the presence of STI increases the risk of HIV acquisition in this context. What is fueling this increase, and . . .